A Victory for Women’s Health

The American College of Obstetricians and Gynecologists today recommended annual mammograms for women 40-49, modifying earlier recommendations in what Susan G. Komen for the Cure is hailing as a “victory for women’s health.”  The new recommendations pattern Komen for the Cure’s longstanding position that women of average risk should be getting annual mammograms beginning in their 40s.  Komen Founder and CEO Ambassador Nancy G. Brinker says the new recommendations “should add clarity and weight” to the confusion over when to commence annual mammography.  The College represents 50,000 obstetricians and gynecologists who are often the front line for preventive screenings in women.

Confusion about the issue escalated in November 2009 when the U.S. Preventive Services Task Force (USPSTF) recommended against annual mammography for women of average risk in their 40s. The USPSTF cited potential over-treatment, false positives and resulting anxiety, with no appreciable impact on mortality from the disease.  Komen continued to recommend that mammograms begin at 40, with Brinker noting that there is no question that “early detection saves lives.”

Read more

See Nancy Brinker discuss this topic on the CBS Early Show in the video below:

About the author

avatar
Susan G. Komen has written 289 articles for Susan G. Komen® | Blog

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen and launched the global breast cancer movement. Today, Komen is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure®, we have invested more than $1.9 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world.

There are no responses so far.

New comments are closed.